ERBB2 and breast cancer: In a study of neoadjuvant human epidermal growth factor receptor 2–positive breast cancer, metabolic responses determined by 18FDG PET/CT were evident at 2 weeks posttreatment, and a significant correlation (R2 = 0.81) was observed between the change in SUVmax at weeks 2 and 6 [5].